

Forteo (teriparatide) Prior Authorization Request Form Caterpillar Prescription Drug Benefit



Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

	URGENT			
MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGI	HT (LB/KG): ALLERGIES:			

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi_disclosure_authorization.pdf</u>

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:		

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.

© 2017 – 2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 08/22/2018 CAT0091 04.15.2020







Forteo (teriparatide) Prior Authorization Request Form Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHEI	R MEDICATIONS FOR THIS CONDITION	? YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 Osteoporosis associated with systemic gl Osteoporosis in a male (idiopathic or hyp Osteoporosis in a postmenopausal femal Other Diagnosis ICD-10 C 3. REQUIRED CLINICAL INFORMATION 	oogonadal) e ode(s):			
PRIOR AUTHORIZATION.				
Has the patient had previous treatment with Tymlos (abaloparatide)? 🗆 Yes 🗆 No				
Has the patient ever been treated w ith a bisphosphonate? Yes No <u>If "No"</u> to the above question, does the patient have reflux/GERD or severe renal disease, as defined by a creatinine clearance (CrCl) < 35 mL/min?* Yes No *Please provide documentation				
Has the patient failed (please note that intolerance is not considered a treatment failure) previous treatment with at least one bisphosphonate (i.e., alendronate [Fosamax], Actonel, ibandronate [Boniva], or zoledronic acid [Reclast])? u Yes u No				
Select if the patient has experienced treatment failure with bisphosphonate therapy, as defined by the following:* □ A decline in bone mineral density in g/cm2 of ≥ 3% in the spine and/or hip while on bisphosphonate therapy □ A fracture while being treated with bisphosphonate therapy (fracture must have occurred in the past 3 years) *Please provide documentation				
Has the patient been intolerant to previous treatment with at least one bisphosphonate (i.e., alendronate [Fosamax], Actonel, ibandronate [Boniva], or zoledronic acid [Reclast])*?				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis ar information is received.	e covered on all plans. This request ma	y be denied unless all required		
© 2017 – 2023 by Magellan Rx Management. (All Bights Posserved			

© 2017 – 2023 by Magellan Rx Management, LLC. All Rights Reserved Revision Date: 08/22/2018 CAT0091 04.15.2020









MEMBER'S LAST NAME: _

MEMBER'S FIRST NAME: ____

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



